Is Enclomiphene Actually Dangerous?

The reputation of enclomiphene gets dragged down by a drug it only partially is, and that confusion costs people accurate information when they are trying to make a real decision.

To understand why enclomiphene works the way it does, you need to understand the system it operates in. Your brain and testes are in a constant conversation. The hypothalamus releases a signal called GnRH, which tells the pituitary to release LH and FSH, which travel to the testes and tell them to produce testosterone. When testosterone rises, the brain detects it and quiets the signal. When testosterone drops, the brain amplifies it. This feedback loop is what keeps the system in balance, and estrogen is one of the main signals the brain uses to read where testosterone stands.

That is the whole pathway. Enclomiphene works by interrupting the feedback signal at the beginning of that chain, not at the end.

It does this by blocking something called estrogen receptors in the hypothalamus and pituitary, which are the docking sites that estrogen normally binds to in order to tell the brain to ease off on testosterone production. When enclomiphene occupies those receptors, estrogen cannot deliver that message, so the brain acts as though testosterone is lower than it actually is and keeps pushing the signal forward. LH goes up, the testes get the instruction, and testosterone production increases through the body's own machinery rather than through something injected from outside.

Now here is where clomiphene comes in, because this is where most of the confusion lives.

Clomiphene, sold as Clomid, is not the same compound as enclomiphene. Clomiphene is a mixture of two molecules called isomers, which are molecules that share the same atoms but are arranged differently, the way your left and right hands are made of the same parts but are mirror images of each other. One of those isomers is enclomiphene, making up about 62 percent of the mixture. The other is something called zuclomiphene, making up the remaining 38 percent.

These two isomers do essentially opposite things.

Enclomiphene blocks estrogen receptors, which is the mechanism that raises testosterone. Zuclomiphene activates estrogen receptors, which works against that effect. And zuclomiphene has a half-life measured in days, meaning it accumulates in the body over time, while enclomiphene clears in roughly 10 hours. So when someone takes clomiphene, they are getting the molecule that raises testosterone paired with a molecule that does the opposite and lingers in the body longer, and that combination is where the side effect profile comes from.

The mood swings, the visual disturbances, the decreased libido that people associate with Clomid are largely attributed to the estrogenic activity of zuclomiphene, not to enclomiphene itself. Saying enclomiphene is dangerous because Clomid has side effects is like blaming one ingredient for what the whole recipe produces.

The research makes this separation concrete. A 2024 study out of Baylor compared clomiphene directly against enclomiphene in 66 men and tracked side effects across both groups. On clomiphene, 47 percent of men reported side effects. On enclomiphene, that number dropped to 13.8 percent. Mood changes affected 9.1 percent of the clomiphene group and zero percent of the enclomiphene group. Decreased libido went from 33.3 percent down to 8.6 percent. And when the researchers measured estradiol, enclomiphene actually decreased it while clomiphene raised it, which makes sense given that zuclomiphene is activating estrogen receptors throughout the body.

A 2025 meta-analysis pulling together 10 randomized controlled trials and 819 patients found that 21 percent of participants experienced some adverse event across the combined data, but none of the adverse events were classified as severe. That is across all the published trial data on these compounds.

Earlier work gives the efficacy picture. A 2013 trial in 44 men found that 25 mg of enclomiphene brought average testosterone to 604 ng/dL over six weeks, with no measurable effects on thyroid function, cortisol, lipid panels, or bone markers. A 2014 study running three months in 124 men found testosterone rising from 217 to 472 ng/dL at a 12.5 mg dose, with sperm counts preserved at a mean of 176 million per milliliter. This is one of the practical advantages enclomiphene holds over testosterone replacement, which suppresses the pituitary signal and typically drives sperm production down toward zero.

There are things the data cannot yet answer, and those matter too.

The longest published follow-up in any of these trials is around six months, so there is no long-term safety data beyond that window. The branded version called Androxal went through the FDA approval process and was rejected, though the rejection was over study design issues rather than concerns about safety or harm. Because no branded version came to market, enclomiphene is mostly available through compounding pharmacies, and that means product quality depends on the specific pharmacy, which is a real variable worth considering.

So the accurate summary is this: the side effects most people associate with enclomiphene actually belong to clomiphene, and specifically to the zuclomiphene portion of it. The published data on enclomiphene alone shows a substantially cleaner side effect profile than the drug it is often confused with, no severe adverse events across any published trial, and efficacy that holds across multiple studies and designs.

The reason this distinction matters beyond academic interest is that a lot of people are either avoiding a compound they might benefit from, or taking the wrong one because the names sound similar and the information floating around treats them as interchangeable.

They are not the same compound, and the difference between them is not subtle.

---

References

1. Saffati G, Kassab J, Orozco Rendon D, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Translational Andrology and Urology. 2024;139:1979-1987. Finding: Side effects: clomiphene 47% vs enclomiphene 13.8% p=0.001. Mood changes: 9.1% vs 0% p=0.03. Decreased libido: 33.3% vs 8.6% p=0.001. Estradiol decreased with enclomiphene, increased with clomiphene p=0.001. Source
2. Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. 2025. Finding: 10 RCTs, 819 patients. SERM therapy increased total testosterone by 273.76 ng/dL vs placebo p<0.01. 21% experienced adverse events; none were severe. Source
3. Wiehle RD, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism. BJU International. 2013;1128:1188-1200. Finding: 44 men, 6 weeks. 25 mg enclomiphene averaged 604 ng/dL testosterone. No effects on TSH, ACTH, cortisol, lipids, or bone markers. Source
4. Wiehle R, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia. Fertility and Sterility. 2014;1023:720-727. Finding: 124 men, 3 months. Testosterone rose from 217 to 472 ng/dL 12.5 mg. Sperm counts preserved mean 176 million/mL. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness